IONS * Stock Overview
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Ionis Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$900.00 |
| 52 Week High | US$900.00 |
| 52 Week Low | US$737.51 |
| Beta | 0.40 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 2.01% |
| 5 Year Change | n/a |
| Change since IPO | -33.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| IONS * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how IONS * performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how IONS * performed against the MX Market.
Price Volatility
| IONS * volatility | |
|---|---|
| IONS * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: IONS * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IONS *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 927 | Brett Monia | www.ionispharma.com |
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus.
Ionis Pharmaceuticals, Inc. Fundamentals Summary
| IONS * fundamental statistics | |
|---|---|
| Market cap | Mex$104.68b |
| Earnings (TTM) | -Mex$6.07b |
| Revenue (TTM) | Mex$13.05b |
8.0x
P/S Ratio-17.2x
P/E RatioIs IONS * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IONS * income statement (TTM) | |
|---|---|
| Revenue | US$787.65m |
| Cost of Revenue | US$907.10m |
| Gross Profit | -US$119.45m |
| Other Expenses | US$246.84m |
| Earnings | -US$366.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.51 |
| Gross Margin | -15.17% |
| Net Profit Margin | -46.50% |
| Debt/Equity Ratio | 329.6% |
How did IONS * perform over the long term?
See historical performance and comparison